Evidence map›Paper›PMID 40416783›Full record

ArticleMaterials today. Bio2025

ECM characterization and 3D bioprinted models of NSCLC for investigating stiffness-dependent tumor behavior and drug response.

Shiwei Xu, Xin Sun, Yexin Gu, Tong Liu, Shiyin Liu, Yuan Weng, Weimin Zhang, Leisheng Wang, Mengzhen Zhou, Guye Lu and 3 more

Abstract read
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shiwei XuDepartment of Thoracic Surgery, Afflicated Hospital of Jiangnan University, Wuxi, 214122, China.
Xin SunJiangsu Hansoh Pharmaceutical, Shanghai, 200120, China.
Yexin GuCyberiad Biotechnology, Shanghai, 201112, China.
Tong LiuWuxi School of Medicine, Jiangnan University, Wuxi, 214000, China.
Shiyin LiuWuxi School of Medicine, Jiangnan University, Wuxi, 214000, China.
Yuan WengDepartment of Thoracic Surgery, Afflicated Hospital of Jiangnan University, Wuxi, 214122, China.
Weimin ZhangDepartment of Thoracic Surgery, Afflicated Hospital of Jiangnan University, Wuxi, 214122, China.
Leisheng WangWuxi School of Medicine, Jiangnan University, Wuxi, 214000, China.
Mengzhen ZhouSchool of Medicine, Southeast University, Nanjing, 210009, China.
Guye LuDepartment of Pulmonary Medicine, Wuxi People's Hospital, Wuxi, 214023, China.
Min TangInstitute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Haifeng WangDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, Shanghai, 200433, China.
Jinyou LiDepartment of Thoracic Surgery, Afflicated Hospital of Jiangnan University, Wuxi, 214122, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The heterogeneity and complex extracellular matrix (ECM) characteristics of non-small cell lung cancer (NSCLC) present significant challenges for understanding its pathological mechanisms and advancing precise treatment strategies. This study characterized the physicochemical properties of native NSCLC ECM to inform the biomimetic design of 3D models utilizing biomaterials and light-based 3D bioprinting technologies. A tunable 3D model was constructed that replicates the interfacial structures and matrix stiffness of both lung cancer tissue and adjacent normal tissue. This model elucidates the impact of matrix stiffness on cellular behaviors, including proliferation, invasion, and drug sensitivity, and delineates the role of the CCN1 gene under different mechanical conditions. Specifically, it demonstrates that a reduction in CCN1 expression within soft matrices can attenuate the migratory and proliferative capabilities of tumor cells. Furthermore, primary NSCLC patient-derived bioprinted tissues validated the model fidelity to clinical samples and its predictive potential for responses to combined chemotherapy and immunotherapy. This study establishes a versatile platform for NSCLC modeling and research, advancing biomaterial and bioprinting strategies to replicate the tumor microenvironment and optimize therapeutic approaches.

Indexed as

3D bioprintingExtracellular matrixNon-small cell lung cancerPatient-derived tissueStiffness

Identifiers

PMID40416783
PMCPMC12098162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.